Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05705570
Title A Phase I Clinical Trial Using Genetically Engineered Autologous T Cells to Express Chimeric Antigen Receptor (CAR) for Treatment of Patients With Refractory or Relapsed CD19-positive B Lymphoid Malignancies (CARTHIAE-1)
Acronym CARTHIAE-1
Recruitment Not yet recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Hospital Israelita Albert Einstein
Indications
Therapies
Age Groups: child | adult | senior
Covered Countries


No variant requirements are available.